Soluble PD-L1 as an early marker of progressive disease on nivolumab

• David F McDermott,
• Gordon J Freeman,
• Toni K Choueiri,
• Petra Ross-MacDonald,
• F Stephen Hodi,
• Megan Wind-Rotolo,
• Long Yuan,
• Kathleen M Mahoney,
• Linan Song,
• Eliseo Veras

Affiliations

David F McDermott

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Gordon J Freeman

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Toni K Choueiri

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Petra Ross-MacDonald

Bristol-Myers Squibb Co, Princeton, New Jersey, USA

F Stephen Hodi

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Megan Wind-Rotolo

Bristol-Myers Squibb Co, Princeton, New Jersey, USA

Long Yuan

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Kathleen M Mahoney

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Linan Song

Quanterix Corporation, Billerica, Massachusetts, USA

Eliseo Veras

Quanterix Corporation, Billerica, Massachusetts, USA